Shimadzu Launches Blood-Based Amyloid Mass Spectrometry Service in North America for Supporting Alzheimer’s Disease Drug Discovery and Development
Shimadzu Scientific Instruments announces the successful commercialization of a new Amyloid Mass Spectrometry (MS) Service for the early screening of amyloid-positive individuals. This simple, research-use-only blood-based analysis method enables reliable characterization of amyloid pathology in the brain with an easy-to-acquire blood sample to assist in the evaluation and development of new pharmaceutical treatments for Alzheimer’s disease.
COLUMBIA, Md., July 8, 2022 /PRNewswire-PRWeb/ — Shimadzu Scientific Instruments announces the successful commercialization of a new Amyloid Mass Spectrometry (MS) Service for the early screening of amyloid-positive individuals. This simple, research-use-only blood-based analysis method enables reliable characterization of amyloid pathology in the brain with an easy-to-acquire blood sample to assist in the evaluation and development of new pharmaceutical treatments for Alzheimer’s disease.
Although the screening analysis is for research use only and cannot diagnose Alzheimer’s disease, it is ideal for opening the door to new advancements in research, identifying suitable candidates for clinical trials and helping pharmaceutical companies in their testing of candidate drugs.
Unlike conventional positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing methods, Shimadzu’s blood amyloid-beta analysis method is minimally invasive and suitable for large-scale deployment. This new approach to blood analysis is capable of being used for predicting abnormal amyloid-beta concentration, which can be a marker for amyloid pathology in the brain. New blood-based biomarkers were discovered in 2014 by Shimadzu Corporation and the Japanese National Center for Geriatrics and Gerontology (NCGG).
The blood analysis works using a combination of immunoprecipitation and MALDI-TOF mass spectrometry (IP-MS). This technique was first established by a team of scientists including Shimadzu’s Koichi Tanaka, who was awarded the Nobel Prize in chemistry in 2002 for developing a method for mass spectrometric analysis of biological macromolecules.
Experts from Shimadzu will present information about the Amyloid Mass Spectrometry (MS) Service at booth 206 at the Alzheimer’s Association International Conference from July 31–August 4, 2022, in San Diego, California.
For more information about Shimadzu’s Amyloid MS Service, visit https://www.ssi.shimadzu.com/products/life-science-lab-instruments/shimadzu-amyloid-ms-service/index.html.
Find more scientific background about Shimadzu’s blood amyloid-beta analysis here: A. Nakamura, N. Kaneko et al., “High performance plasma amyloid-β biomarkers for Alzheimer’s disease” doi: 10.1038/nature 25456. https://www.nature.com/articles/nature25456
Amyloid MS is a trademark of Shimadzu Corporation. For Research Use Only. Not for use in diagnostic procedures.
About Shimadzu Scientific Instruments Inc.
Shimadzu Scientific Instruments (SSI) is the North American subsidiary of Shimadzu Corporation’s Analytical and Measuring Division. Headquartered in Columbia, Maryland, SSI offers a comprehensive portfolio of analytical and testing solutions for a broad range of applications in science and industry. SSI maintains a network of ten regional offices strategically located across the United States, with experienced technical specialists, service providers and sales engineers situated throughout the country. In addition, SSI operates a Solution Center, designed to enable applications development, and an Innovation Center that houses a team of scientists whose goal is to develop close collaborations with universities, government agencies and industry centers. Visit http://www.ssi.shimadzu.com for more information.
Lisa Goetz, Shimadzu Scientific Instruments, 610-269-2100 x244, [email protected]
SOURCE Shimadzu Scientific Instruments
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheTechOutlook.com takes no editorial responsibility for the same.